Interní Med. 2009; 11(4): 159-162 [Med. Pro Praxi 2008; 5(10): 354-357]

Clinical characteristics, diagnostic aspects, prevention, and treatment of resistant hypertension

prof. MUDr. Jaroslav Šimon DrSc
Centrum preventivní kardiologie, II. interní klinika LF UK Plzeň

Resistant hypertension is a commonly occurring clinical phenomenon in both general and specialized practice. The prevalence is not

precisely known, with elderly persons, obese individuals, and those with metabolic syndrome being more frequently affected. Occasional

elevations in blood pressure due to psychosomatic causes and in anxiety and panic episodes need to be distinguished. Permanent

resistance requires ambulatory monitoring of blood pressure and an intensive search for a secondary cause of hypertension. Initial

interventions should involve lifestyle modifications. Pharmacological treatment consists in triple or quadruple combinations of drugs

based on the guidelines and the administration of sufficient doses of diuretics. The addition of low doses of spironolactone has proved

beneficial in some cases.

Keywords: resistant hypertension, pseudohypertension, white coat hypertension.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šimon J. Clinical characteristics, diagnostic aspects, prevention, and treatment of resistant hypertension. Interní Med. 2009;11(4):159-162.
Download citation

References

  1. Česká společnost pro hypertenzi. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verse 2007 Hypertenze, bull ČSH 2008; 9: 9-26.
  2. Task Force of the European Society of Hypertension and of the European Society of Cardiology 2007 Guidelines for the Management of Arterial Hypertension. J. Hypert. 2007; 25: 1105-1187. Go to original source...
  3. Calhoun DA, Ones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association, Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526. Go to original source... Go to PubMed...
  4. Fairbanks VF, Klee GG, Wiseman GA, et al Measurement of blood volume and red cell mass: reexamination of 51C and 125 I methods. Blood Cells Mol. Dis. 1996; 22: 169-186. Go to original source... Go to PubMed...
  5. Roche SL, Kaufmann J, Dipchand AI, et al. Hypertensiom after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J. Heart Lung Transplant 2008; 27: 501-507. Go to original source... Go to PubMed...
  6. Lane DA, Shah S, Beevers DG. Low-dose spironolacton in management of resistant hypertension: a surveillance study J. Hypert. 2007; 25: 891-894. Go to original source... Go to PubMed...
  7. Zannad F. Aldosteron antagonist therapy in resistant hypertension. J. Hypert 2007; 25: 747-750. Go to original source... Go to PubMed...
  8. Enseleit F, Luescher TF, Ruschitzka F. Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin. Investig. Drugs 2008; 17: 1255-1263. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.